Merck and Moderna have 'lot of exploring to do' after initial cancer vaccine success

Speaking at the STAT Summit, Moderna's Stephen Hoge and Merck's Dean Li said the companies will pair Keytruda with personalized mRNA vaccines to target tumors, and that after initial success there is a 'lot of exploring to do.' The provided context does not include specific efficacy data.

Headlines are indexed or machine translated, not independent verification of scientific results. Medical news is not clinical advice. Distinguish interstellar concepts from demonstrated space technology using the original source.